Last reviewed · How we verify
Cortrosyn (tetracosactide)
Cortrosyn (generic name: tetracosactide) is a Adrenocorticotropic Hormone [EPC] drug developed by Amphastar Pharms Inc. It is currently FDA-approved (first approved 1970) for Adrenocortical insufficiency screening.
Cortrosyn is a medication that acts as an agonist to the melanocortin receptor 2, specifically targeting the adrenocorticotropic hormone receptor. It is used as a diagnostic agent in the ACTH stimulation test and has been studied for various conditions, including post-dural puncture headache and type 2 diabetes.
At a glance
| Generic name | tetracosactide |
|---|---|
| Sponsor | Amphastar Pharms Inc |
| Drug class | Adrenocorticotropic Hormone [EPC] |
| Target | Melanocortin receptor 4 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1970 |
Approved indications
- Adrenocortical insufficiency screening
Common side effects
- hypertension
- peripheral edema
- rash
- tachycardia
- bradycardia
Key clinical trials
- Updated Diagnostic Cortisol Values for Adrenal Insufficiency (NA)
- Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4) (EARLY_PHASE1)
- Stress and the Nervous System (NA)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE) (PHASE2)
- Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease (EARLY_PHASE1)
- Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cortrosyn CI brief — competitive landscape report
- Cortrosyn updates RSS · CI watch RSS
- Amphastar Pharms Inc portfolio CI
Frequently asked questions about Cortrosyn
What is Cortrosyn?
What is Cortrosyn used for?
Who makes Cortrosyn?
What is the generic name of Cortrosyn?
What drug class is Cortrosyn in?
When was Cortrosyn approved?
What development phase is Cortrosyn in?
What are the side effects of Cortrosyn?
What does Cortrosyn target?
Related
- Drug class: All Adrenocorticotropic Hormone [EPC] drugs
- Target: All drugs targeting Melanocortin receptor 4
- Manufacturer: Amphastar Pharms Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adrenocortical insufficiency screening